vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and TREASURE GLOBAL INC (TGL). Click either name above to swap in a different company.
TREASURE GLOBAL INC is the larger business by last-quarter revenue ($182.5K vs $169.0K, roughly 1.1× Aligos Therapeutics, Inc.). On growth, TREASURE GLOBAL INC posted the faster year-over-year revenue change (-12.0% vs -72.1%). Over the past eight quarters, Aligos Therapeutics, Inc.'s revenue compounded faster (-50.7% CAGR vs -83.5%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Treasure Global Inc is a consumer technology company offering integrated digital commerce solutions, customer loyalty rewards programs, and cashless payment services. It primarily operates across Southeast Asian markets, serving individual users and small-to-medium enterprise clients.
ALGS vs TGL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $182.5K |
| Net Profit | — | $-2.1M |
| Gross Margin | — | 0.7% |
| Operating Margin | — | -953.5% |
| Net Margin | — | -1169.1% |
| Revenue YoY | -72.1% | -12.0% |
| Net Profit YoY | 75.8% | -124.5% |
| EPS (diluted) | — | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | — | ||
| Q3 25 | $741.0K | $182.5K | ||
| Q2 25 | $965.0K | $1.2M | ||
| Q1 25 | $311.0K | $666.5K | ||
| Q4 24 | $606.0K | $301.9K | ||
| Q3 24 | $1.3M | $207.4K | ||
| Q2 24 | $1.1M | $293.0K | ||
| Q1 24 | $694.0K | $1.6M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-2.1M | ||
| Q2 25 | $-15.9M | — | ||
| Q1 25 | $43.1M | $1.3M | ||
| Q4 24 | $-82.2M | $-232.3K | ||
| Q3 24 | $-19.3M | $-950.7K | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $-34.9M | $-1.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 68.2% | ||
| Q1 25 | — | 73.0% | ||
| Q4 24 | — | 74.2% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 31.0% | ||
| Q1 24 | — | 13.6% |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -953.5% | ||
| Q2 25 | -1924.0% | — | ||
| Q1 25 | -6187.5% | -6.5% | ||
| Q4 24 | -3393.2% | -229.5% | ||
| Q3 24 | -1610.5% | -391.4% | ||
| Q2 24 | -2489.5% | — | ||
| Q1 24 | -3176.7% | -85.9% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -1169.1% | ||
| Q2 25 | -1643.8% | — | ||
| Q1 25 | 13854.7% | 189.0% | ||
| Q4 24 | -13556.1% | -77.0% | ||
| Q3 24 | -1540.7% | -458.5% | ||
| Q2 24 | 477.0% | — | ||
| Q1 24 | -5023.5% | -107.3% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | $-0.38 | ||
| Q2 25 | $-1.53 | — | ||
| Q1 25 | $-2.11 | $1.09 | ||
| Q4 24 | $-13.10 | $-11.32 | ||
| Q3 24 | $-3.07 | $-17.62 | ||
| Q2 24 | $0.81 | — | ||
| Q1 24 | $-5.58 | $-116.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $53.5M | $12.0M |
| Total Assets | $88.5M | $16.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | $2.5K | ||
| Q4 24 | $56.9M | $504.3K | ||
| Q3 24 | $74.9M | $44.1K | ||
| Q2 24 | $94.5M | $171.6K | ||
| Q1 24 | $112.7M | — |
| Q4 25 | $53.5M | — | ||
| Q3 25 | $71.8M | $12.0M | ||
| Q2 25 | $101.9M | $10.7M | ||
| Q1 25 | $116.4M | $29.1M | ||
| Q4 24 | $-29.0M | $18.4M | ||
| Q3 24 | $50.1M | $6.3M | ||
| Q2 24 | $67.2M | $3.4M | ||
| Q1 24 | $59.8M | $3.1M |
| Q4 25 | $88.5M | — | ||
| Q3 25 | $109.8M | $16.6M | ||
| Q2 25 | $134.7M | $14.9M | ||
| Q1 25 | $150.7M | $30.4M | ||
| Q4 24 | $70.1M | $19.1M | ||
| Q3 24 | $88.4M | $7.1M | ||
| Q2 24 | $108.8M | $4.3M | ||
| Q1 24 | $127.9M | $4.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.4M |
| FCF MarginFCF / Revenue | — | -1318.2% |
| Capex IntensityCapex / Revenue | — | 353.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | — | ||
| Q3 25 | $-24.3M | $-1.8M | ||
| Q2 25 | $-15.5M | $-9.5M | ||
| Q1 25 | $-20.9M | $-4.2M | ||
| Q4 24 | $-18.4M | $-606.2K | ||
| Q3 24 | $-20.1M | $-976.3K | ||
| Q2 24 | $-19.5M | $-4.7M | ||
| Q1 24 | $-22.7M | $-1.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | — | $-9.5M | ||
| Q1 25 | — | $-4.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-4.7M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | -1318.2% | ||
| Q2 25 | — | -822.4% | ||
| Q1 25 | — | -635.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1614.2% | ||
| Q1 24 | — | -67.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 353.3% | ||
| Q2 25 | — | 1.3% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 5.7% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | -3.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
